$3.24
+0.08 (+2.53%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where RNAZ is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 0 tracked-famous managers · FINRA short interest 1.8 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Study of TTX-MC138 in Subjects With Advanced Solid TumorsNCT06260774Dose Escalation - Adverse EventsNon-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: TTX-MC138 | Advanced Solid Tumor | 16 | 2025-09-30actual | 2025-10-02 |
| A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid TumorsNCT05908773Injected DoseOpen-label · Other | Early Phase 1 | Completed | Drug: TTX-MC138-NODAGA-Cu64 | Advanced Solid Tumor | 1 | 2023-08-23actual | 2025-01-28 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19